Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced instrument shipments and preliminary unaudited fourth quarter 2022 revenue.
The company shipped five G4 instruments through December 31, 2022 and recognized approximately $700 thousand in preliminary unaudited revenue during the fourth quarter 2022 for those instruments that met revenue recognition criteria.
“We are pleased to have finished the year on a strong note. We executed to our plan in Q4, shipping several G4 systems which are now installed and running in customer labs,” said Drew Spaventa, Chairman and Chief Executive Officer. “In 2023, we will remain focused on scaling production of G4 instruments, expanding our customer base, and advancing development of our product roadmap.”
https://finance.yahoo.com/news/singular-genomics-reports-instrument-shipments-110000885.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.